The druggable genome
Top Cited Papers
- 1 September 2002
- journal article
- research article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 1 (9) , 727-730
- https://doi.org/10.1038/nrd892
Abstract
An assessment of the number of molecular targets that represent an opportunity for therapeutic intervention is crucial to the development of post-genomic research strategies within the pharmaceutical industry. Now that we know the size of the human genome, it is interesting to consider just how many molecular targets this opportunity represents. We start from the position that we understand the properties that are required for a good drug, and therefore must be able to understand what makes a good drug target.Keywords
This publication has 15 references indexed in Scilit:
- The end of the beginning for genomic medicineNature Biotechnology, 2001
- The Sequence of the Human GenomeScience, 2001
- Initial sequencing and analysis of the human genomeNature, 2001
- A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutationsNature Biotechnology, 2001
- The InterPro database, an integrated documentation resource for protein families, domains and functional sitesNucleic Acids Research, 2001
- Metabolite profiling for plant functional genomicsNature Biotechnology, 2000
- Drug Discovery: A Historical PerspectiveScience, 2000
- Drug Development: The role of innovation in drug developmentNature Biotechnology, 1997
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdvanced Drug Delivery Reviews, 1997
- Genomic sciences and the medicine of tomorrowNature Biotechnology, 1996